Pulmonary Drugs Market
- 2026 年市場規模
- USD 56.6 Bn
- 2033 年預估規模
- USD 96.5 Bn
- 年複合成長率 CAGR
- 8.1%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Pulmonary Drugs Market, By Drug Class (Inhaled Corticosteroids, Long Acting Beta-2 Agonists, Antihistamines, Vasodilators, Short Acting Beta-2 Agonists, Others), By Application (Asthma & COPD, Allergic Rhinitis, Pulmonary Arterial Hypertension, Cystic Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
報告摘要
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
Market Dynamics
The major factors driving growth of the pulmonary drugs market include increasing incidence of chronic respiratory diseases, tobacco smoking, and government and non-government initiatives. According to Center for Disease Control and Prevention (CDC), in 2015, 25 million people in the U.S. suffered from asthma that is 1 in 13 Americans were suffering from asthma. Under 18 years of age, 6.2 million people suffered from asthma. Annually asthma accounts for 14.2 million physician office visits and 1.8 million emergency visits. Moreover, the significant number of patent expiration of branded drugs, funding for research and development and launch of innovative products are expected to contribute as major factors in the market growth over the forecast period. For instance, in 2017, GSK received U.S. FDA approval for unique three-in-one inhaler named Trelegy Ellipta for chronic lung disease. Trelegy Ellipta combines three therapies into a single inhaler, thereby giving a new treatment option to the patients. However, a large undiagnosed population and side effects associated with the consumption of these drugs resulting into kidney problems leading to adverse outcomes are expected to limit the market growth.
Key features of the study
• This report provides in-depth analysis of pulmonary drugs market and provides market size (USD Bn) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2026 – 2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by the leading players
• It profiles leading players in the global pulmonary drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, and strategies, and future plans
• Key companies covered as a part of this study include Sanofi SA, Meda Pharmaceuticals, Circassia Pharmaceuticals Plc., AstraZeneca Plc., GlaxoSmithKline Plc., Mallinckrodt Pharmaceuticals Plc., Cheisi Farmaceuticals S.p.A, Zambon Company S.p.A, Alaxia SAS, and Merck Sharp & Dohme Limited
• Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
• The global pulmonary drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the pulmonary drugs market
Market Segmentation
• Drug Class Insights (Revenue, USD Bn, 2026 - 2033)
o Inhaled Corticosteroids
o Long Acting Beta-2 Agonists
o Antihistamines
o Vasodilators
o Short Acting Beta-2 Agonists
o Others
• Application Insights (Revenue, USD Bn, 2026 - 2033)
o Asthma & COPD
o Allergic Rhinitis
o Pulmonary Arterial Hypertension
o Cystic Fibrosis
o Others
• Distribution Channel Insights (Revenue, USD Bn, 2026 - 2033)
o Hospital Pharmacies
o Retail Pharmacies
o E-Commerce
• Regional Insights (Revenue, USD Bn, 2026 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players Insights
o Sanofi SA
o Meda Pharmaceuticals
o Circassia Pharmaceuticals Plc.
o AstraZenca Plc.
o GlaxoSmithKline Plc.
o Mallinckrodt Pharmaceuticals Plc.
o Cheisi farmaceutici S.p.A.
o Zambon Company S.p.A.
o Alaxia SAS
o Merck Sharp & Dohme Limited
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Class
Market Snapshot, By Application
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Regulatory Scenario
o Pipeline Analysis
o Promotional Activities and Campaigns
o Supply Chain Analysis
o PEST Analysis
o Epidemiology
4. Global Pulmonary Drugs Market, By Drug Class, 2026 – 2033, (USD Bn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Inhaled Corticosteroids
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Long Acting Beta-2 Agonists
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Antihistamines
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Vasodilators
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Short Acting Beta-2 Agonists
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Others
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
5. Global Pulmonary Drugs Market, By Application, 2026 – 2033, (USD Bn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Asthma & COPD
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Allergic Rhinitis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Pulmonary Arterial Hypertension
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Cystic Fibrosis
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Others
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
6. Global Pulmonary Drugs Market, By Distribution Channel, 2026 – 2033, (USD Bn)
o Overview
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Hospital Pharmacies
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o Retail Pharmacies
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
o E-Commerce
Market Share Analysis, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, 2021 - 2033
Segment Trends
7. Global Pulmonary Drugs Market, By Region, 2026 – 2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
Y-o-Y Growth Analysis, For Region, 2021 - 2033
o North America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o U.S.
o Canada
o Latin America
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o UK
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o GCC Countries
o Israel
o Rest of Middle East
o Africa
Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
Y-o-Y Growth Analysis, For Country, 2021 - 2033
Market Size and Forecast, By Drug Class, 2026- 2033, (USD Bn)
Market Size and Forecast, By Application, 2026- 2033, (USD Bn)
Market Size and Forecast, By Distribution Channel, 2026- 2033, (USD Bn)
Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis (3x3 Matrix)
o Company Profiles
Sanofi SA
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
Meda Pharmaceuticals
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
Circassia Pharmaceuticals Plc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
AstraZeneca Plc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
GlaxoSmithKline Plc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
Mallinckrodt Pharmaceuticals Plc.
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
Cheisi Farmaceutici S.p.A
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
Zambon Company S.p.A
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
Alaxia SAS
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
Merck Sharp & Dohme Limited
o Company Overview
o Product Portfolio
o Financial Performance
o Recent Developments/Updates
o Future Plans
o Analyst Views
9. Section
o References
o Research Methodology
o About Us and Sales Contact
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們